Finasteride Monitoring for Adults 30 to 49: Labs, Timelines, and What to Track

Is there a standard lab schedule for finasteride at this age?

No. The Propecia label does not set a routine laboratory schedule for men taking 1 mg for male pattern hair loss. Its warnings and precautions section deals with a single laboratory test, PSA, and the rest of its safety information is about clinical effects rather than blood work [1].

Within 24 hours, a single 1 mg tablet suppresses serum DHT by 65%, while mean circulating testosterone and estradiol rise by about 15% and remain inside the normal range [1]. Because the type II enzyme complex turns over slowly, with a half-life of about 30 days, the DHT effect outlasts the 5 to 6 hour plasma half-life of the drug [1].

The label's laboratory guidance is about PSA interpretation; its safety sections cover sexual function and mood.

PSA: the one laboratory value the label addresses

Finasteride lowers PSA, which changes what a result means. In the Propecia studies in men aged 18 to 41, mean PSA went from 0.7 ng/mL at baseline to 0.5 ng/mL at month 12 [1]. The Proscar label, which covers the 5 mg dose used for benign prostatic hyperplasia, puts the effect at about 50% within six months and says a new PSA baseline should be established at least six months after starting, with an isolated PSA after six months doubled for comparison with normal ranges in untreated men [3].

Both labels agree on what to do with a rise: any confirmed increase from the lowest PSA value while on treatment may signal prostate cancer and should be evaluated, even if the value is still normal for a man not taking a 5-alpha reductase inhibitor [1][3]. The Proscar label adds that percent free PSA stays constant, so no adjustment to it appears necessary, and that missed doses can affect results [3].

The doubling rule and the six-month re-baseline are written into the Proscar (5 mg, BPH) label [3]. The Propecia label describes the PSA effect in younger men and the rule about confirmed increases, without a doubling instruction [1]. Both labels also carry the warning that 5-alpha reductase inhibitors may increase the risk of high-grade prostate cancer: in the 7-year Prostate Cancer Prevention Trial of 5 mg in men 55 and older, Gleason 8 to 10 cancer was found in 1.8% on finasteride versus 1.1% on placebo, and the Propecia label states that the clinical significance of that finding for men taking 1 mg is unknown [1][3].

Sexual function: what to ask about and what the numbers are

In the three 12-month controlled Propecia trials (945 men on 1 mg, 934 on placebo, aged 18 to 41), one or more drug-related sexual events were reported by 3.8% versus 2.1% on placebo (p=0.04). Decreased libido was 1.8% versus 1.3%, erectile dysfunction 1.3% versus 0.7%, and ejaculation disorder 1.2% versus 0.7%; 1.2% versus 0.9% stopped treatment because of a sexual event [1]. Resolution occurred in the men who discontinued for these effects and in most who continued, and the incidence of each fell to 0.3% or lower by the fifth year [1].

A 2019 meta-analysis of 15 randomized placebo-controlled trials (4,495 men with androgenetic alopecia) found a 1.57-fold relative risk of sexual dysfunction with 5-alpha reductase inhibitors (95% CI 1.19 to 2.08), and 1.66 (1.20 to 2.30) for finasteride 1 mg [2]. A separate review of 34 finasteride trials for hair loss found that none had adequate safety reporting and 76% evaluated safety for one year or less, which limits how precisely the true rate is known [5].

The label's postmarketing section goes further than the trial tables: it lists sexual dysfunction that continued after discontinuation, including erectile dysfunction and libido, ejaculation and orgasm disorders [1]. These are voluntary reports from a population of uncertain size, and the labels state that a causal relationship cannot reliably be established [1][3].

Mood: the label wording and the cohort data

Depression, suicidal ideation and behavior appear in the Propecia label's postmarketing section, not in a boxed warning; neither Propecia nor Proscar carries a boxed warning [1][3]. The wording has a specific history: the June 2021 label listed postmarketing depression, and on May 31, 2022 the FDA issued a safety labeling change order citing suicidal ideation and behavior, sexual dysfunction and psychoneurocognitive events; the supplement approved on August 1, 2022 changed the label to depression, suicidal ideation and behavior [4].

Observational data come from older men (median age 75 in Ontario; 73 at treatment start in Sweden). In an Ontario cohort of 93,197 men aged 66 or older, 5-alpha reductase inhibitors were not associated with increased suicide (HR 0.88, 95% CI 0.53 to 1.45); self-harm was higher in the first 18 months (HR 1.88, 1.34 to 2.64), and depression was higher in the first 18 months (HR 1.94, 1.73 to 2.16) and afterward (HR 1.22, 1.08 to 1.37) [6]. A Swedish register study of 2,236,876 men aged 50 to 90 found depression associated with finasteride (HR 1.61, 1.48 to 1.75) but no association with suicide (HR 1.22, 0.99 to 1.49) [7]. Neither cohort included men in their 30s.

A small cross-sectional study compared 61 former finasteride users who reported persistent sexual side effects with 29 men with hair loss who had never used it: depressive symptoms (BDI-II score of 14 or more) were present in 75% versus 10% [8]. That design, with self-selected participants, cannot establish cause.

Fertility and semen changes

The 1 mg label reports a small change in ejaculate volume: a median 0.3 mL lower (-11%) versus 0.2 mL lower (-8%) on placebo after 48 weeks [1]. A dedicated 48-week study of 181 men aged 19 to 41, with 79 in the semen substudy, found no significant effect of 1 mg daily on sperm concentration, total sperm per ejaculate, motility or morphology, and the ejaculate-volume difference between groups was not significant [9]. The 5 mg label reports no clinically meaningful effect on sperm concentration, motility, morphology or pH over 24 weeks, alongside a 0.6 mL (22.1%) median fall in ejaculate volume that was reversible, with an average 84 weeks to return to baseline [3].

Postmarketing reports in the label include male infertility and poor seminal quality, with normalization or improvement reported after discontinuation [1]. That wording is the label's fertility-related information.

Liver and drug interactions

Finasteride is extensively metabolized in the liver, mainly by CYP3A4, with metabolites excreted roughly 39% in urine and 57% in feces [1]. The Propecia label says caution should be exercised in patients with liver function abnormalities, and does not call for liver testing [1]. The interactions section reports that no drug interactions of clinical importance have been identified and that finasteride does not appear to affect the cytochrome P450 system; it was tested with antipyrine, digoxin, propranolol, theophylline and warfarin without meaningful interaction [1].

What the label says about response and follow-up

Benefit is judged in months, not weeks: daily use for three months or more is usually needed before benefit is observed, and withdrawal of treatment reverses the effect within 12 months [1]. In the two 1-year trials of 1,553 men aged 18 to 41, hair count in a 1-inch (5.1 cm2) circle of vertex scalp was 107 hairs higher than placebo at one year and 138 higher at two years, while the placebo group kept losing hair [10].

The prescription itself is simple, one 1 mg tablet once daily with or without food [1], and HealthRX.com offers finasteride 1 mg by prescription.

For Proscar 5 mg, the label says to establish a new PSA baseline at least six months after starting treatment and to double an isolated PSA value after six months when comparing it with untreated ranges [3]. Both labels say that any confirmed rise from the lowest PSA value on treatment should be evaluated [1][3]. Sexual function and mood appear in the label's adverse reaction and postmarketing sections [1].